Related Experiment Video
Updated: Aug 2, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors
1Vall d'Hebron University Hospital, Universidad Autónoma de Barcelona, Barcelona, Spain.
Abstract:
The identification of somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and their correlation with response to EGFR inhibitors has become an important event in the fields of cancer genetics and therapeutics. The initial observation of a higher response to gefitinib and erlotinib in patients of Asian origin was followed by the discovery that they harbor more frequent EGFR mutations in NSCLC; this raises the issue of ethnic diversity in the pathogenesis of given tumors. In a similar fashion, amplification of the closely related HER2 gene, which could also have implications for the treatment of NSCLC, is also more frequent in East Asian patients. On the other hand, EGFR gene amplification may be more prevalent in Western populations. The implication of these findings is that ethnicity may indicate different genetic backgrounds in common tumors that may influence clinical outcome and response to therapy. Therefore, in clinical trials with tyrosine kinase inhibitors and other molecular-targeted therapies, the inclusion of a global population appears to be required.
Insights
Ethnic variations in cancer genetics, like epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC), impact treatment response. Understanding these differences is crucial for developing targeted therapies.
Area of Science:
- Oncology
- Cancer Genetics
- Pharmacogenomics
Background:
- Somatic mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain are key in non-small-cell lung cancer (NSCLC) treatment.
- Observed ethnic differences in response to EGFR inhibitors suggest underlying genetic variations in NSCLC pathogenesis.
- HER2 gene amplification and EGFR gene amplification show distinct prevalence across ethnic groups, impacting NSCLC treatment strategies.
Purpose of the Study:
- To investigate the influence of ethnic diversity on the genetic background of non-small-cell lung cancer (NSCLC).
- To explore how varying genetic profiles across ethnicities may affect clinical outcomes and response to molecular-targeted therapies.
- To highlight the necessity of including diverse populations in clinical trials for tyrosine kinase inhibitors and other targeted treatments.
Main Methods:
- Review and synthesis of existing research on EGFR mutations and HER2 amplification in NSCLC across different ethnic populations.
- Comparative analysis of mutation frequencies and gene amplification prevalence between Asian and Western populations.
- Correlation of genetic findings with clinical outcomes and response rates to EGFR inhibitors.
Main Results:
- EGFR mutations are more frequent in East Asian patients with NSCLC, correlating with higher response rates to gefitinib and erlotinib.
- HER2 gene amplification is also more common in East Asian populations, with potential therapeutic implications for NSCLC.
- EGFR gene amplification appears more prevalent in Western populations, indicating divergent genetic landscapes in NSCLC.
Conclusions:
- Ethnicity plays a significant role in the genetic predisposition and molecular characteristics of non-small-cell lung cancer (NSCLC).
- These ethnic variations in genetic backgrounds can influence patient response to targeted therapies, including EGFR inhibitors.
- Global population inclusion in clinical trials is essential for validating and optimizing molecular-targeted therapies for NSCLC.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase